Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Healthy Adults After Challenge With Snow Mountain Virus
Sponsor: Cocrystal Pharma, Inc.
Summary
Participants in this study will be given either CDI-988 or placebo orally before receiving a norovirus challenge virus and continuing for 5 days. Participants will not know whether they are getting placebo or CDI-988. The study will evaluate how well CDI-988 compared to placebo can reduce the incidence of clinical symptoms after a challenge with norovirus. The amount of virus in stool samples will be measured over time. Side effects and pharmacokinetics (the amount of CDI-988 in blood) will also be measured.
Official title: A Phase 1b, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Healthy Adults After Challenge With Norovirus
Key Details
Gender
All
Age Range
18 Years - 49 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2026-03-01
Completion Date
2026-12-01
Last Updated
2026-02-17
Healthy Volunteers
Yes
Conditions
Interventions
CDI-988
Antiviral to treat norovirus
Placebo
Matching placebo
Snow Mountain Virus
Challenge with Snow Mountain Virus
Locations (1)
Hope Clinic of the Emory Vaccine Center
Decatur, Georgia, United States